Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.52 |
| ▸ | ITGB6 | P18564 | 10/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.52 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919755 | 0.90 | ITGB3 (0.61) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL6016500 | 0.80 | ITGAV (0.51) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL13237215 | 0.80 | ITGAV (0.58) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL7395076 | 0.79 | ENPP3 (0.37) | ITGB3ITGA2B | |
| SCHEMBL7487509 | 0.78 | ITGB3 (0.81) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL275017 | 0.77 | ITGAV (0.85) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL274691 | 0.77 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL13237209 | 0.76 | ITGAV (0.57) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL13237214 | 0.76 | ITGAV (0.57) | ITGAVITGB3ITGB6ITGB1ITGA5 | |
| SCHEMBL13237208 | 0.76 | ITGB3 (0.55) | ITGAVITGB3ITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2001524079-A | — | — | 2001-11-27 | — | — | JP | claimed |
| EP-0973396-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0973396-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-01-26 | — | — | EP | claimed |
| WO-1998044797-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | claimed |
| EP-0973396-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0973396-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5919792-A | Integrin antagonists | MERCK & CO., INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998044797-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1998-10-15 | — | — | WO | disclosed |